Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 651-661

  Tan, Bee Jen ^a   Liu, Yuanjie ^a   Chang, Kai Lun ^a   Lim, Bennie K W ^a   Chiu, Gigi N C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Lung cancer; PEG PE; Peroral drug delivery; Polymeric micelles; Quercetin

Indexed keywords

COPOLYMER; LACTOSE DEHYDROGENASE; MACROGOL; OXIDOREDUCTASE; PHOSPHATIDYLETHANOLAMINE; QUERCETIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTIOXIDANT; DIOLEOYL N (MONOMETHOXYPOLYETHYLENE GLYCOL SUCCINYL)PHOSPHATIDYLETHANOLAMINE; DIOLEOYL-N-(MONOMETHOXYPOLYETHYLENE GLYCOL SUCCINYL)PHOSPHATIDYLETHANOLAMINE; DRUG CARRIER; MACROGOL DERIVATIVE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SYNTHESIS; ELECTRIC RESISTANCE; ENZYME RELEASE; FEMALE; LUNG CANCER; MICELLE; MOUSE; NONHUMAN; PARTICLE SIZE; SOLUBILIZATION; STOMACH PH; ANALYSIS OF VARIANCE; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; DRUG STABILITY; HUMAN; LUNG TUMOR; ORAL DRUG ADMINISTRATION; PATHOLOGY; PH; TUMOR CELL LINE;

ANIMALIA; MURINAE;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CACO-2 CELLS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG STABILITY; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; LUNG NEOPLASMS; MICE; MICELLES; NANOPARTICLES; PARTICLE SIZE; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; QUERCETIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865630644     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S26538     Document Type: Article

References (30)

1. Clinical Practice Guidelines: Non-small cell lung cancer. National Comprehensive Cancer Network 2008. Available from: http:// www.nccn.org/professionals/physician_gls/PDF/nscl.pdf. Accessed September 19, 2008.
2. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1): 235-249.
3. Teicher BA, Andrews PA. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials and Approval. 2nd ed. Totowa, NJ: Humana Press; 2004.
4. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3-26.
5. Leonarduzzi G, Testa G, Sottero B, Gamba P, Poli G. Design and development of nanovehicle-based delivery systems for preventive or therapeutic supplementation with flavonoids. Curr Med Chem. 2010;17(1):74-95.
6. Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol. 2006;72(11):1439-1452.
7. Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev. 2010;29(3):405-434.
8. Ferry DR, Smith A, Malkhandi J, et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res. 1996;2(4):659-668.
9. Yuan ZP, Chen LJ, Fan LY, et al. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clin Cancer Res. 2006;12(10):3193-3199.
10. Bromberg L. Polymeric micelles in oral chemotherapy. J Control Release. 2008;128(2):99-112.
11. Priprem A, Watanatorn J, Sutthiparinyanont S, Phachonpai W, Muchimapura S. Anxiety and cognitive effects of quercetin liposomes in rats. Nanomedicine. 2008;4(1):70-78.
12. Ghosh A, Mandal AK, Sarkar S, Panda S, Das N. Nanoencapsulation of quercetin enhances its dietary efficacy in combating arsenic-induced oxidative damage in liver and brain of rats. Life Sci. 2009;84(3-4): 75-80.
13. Date AA, Nagarsenker MS, Patere S, et al. Lecithin-based novel cationic nanocarriers (Leciplex) II: improving therapeutic efficacy of quercetin on oral administration. Mol Pharm. 2011;8(3):716-726.
14. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007;24(1):116.
15. Alkan-Onyuksel H, Ramakrishnan S, Chai HB, Pezzuto JM. A mixed micellar formulation suitable for the parenteral administration of taxol. Pharm Res. 1994;11(2):206-212.
16. Gao Z, Lukyanov AN, Chakilam AR, Torchilin VP. PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing. J Drug Target. 2003;11(2):87-92.
17. Goniotaki M, Hatziantoniou S, Dimas K, Wagner M, Demetzos C. Encapsulation of naturally occurring flavonoids into liposomes: physicochemical properties and biological activity against human cancer cell lines. J Pharm Pharmacol. 2004;56(10):1217-1224.
18. van der Woude H, Gliszczynska-Swiglo A, Struijs K, Smeets A, Alink GM, Rietjens IM. Biphasic modulation of cell proliferation by quercetin at concentrations physiologically relevant in humans. Cancer Lett. 2003;200(1):41-47.
19. Schneeberger EE, Lynch RD. The tight junction: a multifunctional complex. Am J Physiol Cell Physiol. 2004;286(6):C1213-C1228.
20. Suzuki T, Hara H. Role of flavonoids in intestinal tight junction regulation. J Nutr Biochem. 2011;22(5):401-408.
21. Erlund I, Kosonen T, Alfthan G, et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol. 2000;56(8):545-553.
22. Conquer JA, Maiani G, Azzini E, Raguzzini A, Holub BJ. Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J Nutr. 1998;128(3):593-597.
23. Dabholkar RD, Sawant RM, Mongayt DA, Devarajan PV, Torchilin VP. Polyethylene glycol-phosphatidylethanolamine conjugate (PEGPE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int J Pharm. 2006;315(1-2):148-157.
24. Collnot EM, Baldes C, Wempe MF, et al. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J Control Release. 2006;111(1-2):35-40.
25. Sezgin Z, Yuksel N, Baykara T. Investigation of pluronic and PEG-PE micelles as carriers of meso-tetraphenyl porphine for oral administration. Int J Pharm. 2007;332(1-2):161-167.
26. Passamonti S, Terdoslavich M, Franca R, et al. Bioavailability of flavonoids: a review of their membrane transport and the function of bilitranslocase in animal and plant organisms. Curr Drug Metab. 2009;10(4):369-394.
27. Suzuki T, Hara H. Quercetin enhances intestinal barrier function through the assembly of zonula [corrected] occludens-2, occludin, and claudin-1 and the expression of claudin-4 in Caco-2 cells. J Nutr. 2009;139(5):965-974.
28. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr. 2005;81(Suppl 1):230S-242S.
29. Sahlin JJ, Peppas NA. Enhanced hydrogel adhesion by polymer interdiffusion: use of linear poly(ethylene glycol) as an adhesion promoter. J Biomater Sci Polym Ed. 1997;8(6):421-436.
30. Ruiz MJ, Fernandez M, Pico Y, et al. Dietary administration of high doses of pterostilbene and quercetin to mice is not toxic. J Agric Food Chem. 2009;57(8):3180-3186.